API MANUFACTURING FACILITY

Biocon received four observations from the US health regulator after a GMP inspection at its API facility in Andhra Pradesh.

Kotak Alternate Asset Managers has announced a Rs 1,445 crore investment in the acquisition of Viatris' active pharmaceutical ingredient (API) business by Matrix Pharma. The investment was made through Kotak Strategic Situations Fund II, as stated i...

The US Food and Drug Administration (FDA) completes inspection of Solara Active Pharma Sciences' API manufacturing facility in Visakhapatnam, Andhra Pradesh, with no observations. Solara confirms compliance with FDA standards. The facility, dedicate...

After India lost its dominance in making penicillin, a drought of three decades is coming to an end. The drug – which forms the base for a raft of extremely potent antibiotics – is part of the govt’s aggressive push for self-sufficiency in critical ...

Kotak is lending $150 million (₹1,250 crore) under a mezzanine debt facility to Prasad at 18-20% and arranging an additional $300 million from other lenders including Edelweiss Domestic Performing Credit Fund, two people close to the development sai...

The Rs 2,400 crore Pen-G plant is expected to start trial production in April and commercial production in a couple of months and the ramping up of the production will happen during the second quarter of the current fiscal, a senior official of the ...

Chemex Global's pharmaceutical API manufacturing facility in Guwahati, first of its kind in the region, positions Assam as the next big pharma hub in India. It aims to expand trade routes with Gujarat, Hyderabad, Sikkim, and Southeast Asia.

The Delhi-based company had reported a revenue of Rs 333.66 crore for the financial year that ended on March 31, 2023. The company gets nearly equal contributions from the B2B and B2C businesses.

“Three years back, when we started, we had a significant debt. But, today we are a debt-free company and we also have significant investment plans. We are well set to not just utilise our QIP cash that we are sitting on, but also generate enough cas...

Mumbai-based drug manufacturer Rusan Pharma has inaugurated a new active pharmaceutical ingredient (API) facility in Pithampur, Madhya Pradesh, with a total investment of up to Rs 300 crores over two phases. The facility, set to be fully operational...

Nimmagadda Prasad, the founder of Matrix Laboratories, has bought back the active pharmaceutical ingredients (API) business he sold to Mylan NV (now Viatris) in 2006. The acquisition was made through IQuest Enterprises, owned by Prasad. Viatris will...

Viatris' latest transaction includes three manufacturing sites and a R&D lab in Hyderabad, three manufacturing sites in Vizag and third-party API sales. Viatris will retain some selective R&D capabilities in API. The transaction is expected to close...

IndiaRF will acquire the active pharmaceutical ingredients (API) and contract research and manufacturing services (CRAMS) business of Ind-Swift Labs for a consideration of Rs 1,650 crore. ET first reported on this transaction on July 21 this year. T...

Torrent Pharmaceuticals on Thursday said that the US Food and Drug Administration (US FDA) has issued an Establishment Inspection Report (“EIR”) for the company's manufacturing facility at Dahej, Gujarat. EIR means closure of inspection.

ET Intelligence Group: Ahmedabad-based Concord Biotech is a global supplier of bio-pharmaceutical APIs and formulations, serving more than 70 countries, including regulated markets like the United States, Europe and Japan.

Healthcare sector performed well through the early phase of Covid, and as such, returns were high in that period. What we have seen is a correction for some time post that stellar initial performance. However, even earnings performance for the large...

Earlier in July 2021, Ind-Swift Laboratories had agreed to sell its API business to PI Industries on a slump sale basis, for ₹1,530 crore. However, the deal had been terminated by PI Industries in November 2021. Incorporated in 1995, IISL is engaged...

Dr Reddy's said it has received establishment inspection report (EIR) for its formulations manufacturing unit in Srikakulam (FTO SEZ PU2), Andhra Pradesh. EIR means closure of inspection. The inspection was conducted from June 12, 2023 to June 16, 2...

As per US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act an...